Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 5345.

https://doi.org/10.1182/blood-2018-99-113117

Published: 2018

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,

Matthew J Ahearne, MBChB MRCP, Kaljit S Bhuller, MBChB MRCP, Roger Hew, MBChB, Giovanna Roncador, Martin J.S. Dyer, MA, DPhil, Daniel B. Kennedy, Fiona Miall, MD, Simon D. Wagner, MBBS, PhD, FRCP

Blood (2011) 118 (21): 3684.

https://doi.org/10.1182/blood.V118.21.3684.3684

Published: 2011

Journal Articles

Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

Robert S Boyd, PhD, Rebekah Jukes-Jones, PhD, Renata Walewska, FRCP, David Brown, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Kelvin Cain, PhD

Blood (2008) 112 (11): 374.

https://doi.org/10.1182/blood.V112.11.374.374

Published: 2008

Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Blood (2008) 112 (11): 328.

https://doi.org/10.1182/blood.V112.11.328.328

Published: 2008

NARROW

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,

Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Email alerts

ASH Publications

American Society of Hematology

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,

Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only